柳紊
Lv1
20 积分
2022-03-09 加入
-
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
12天前
已完结
-
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
2个月前
已完结
-
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
2个月前
已完结
-
Strategies and challenges for the next generation of antibody–drug conjugates
2个月前
已完结
-
Risk of Cytomegalovirus Infection with Post-Transplantation Cyclophosphamide in Haploidentical and HLA-Matched Unrelated Donor Transplantation
4个月前
已完结
-
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
5个月前
已完结
-
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
6个月前
已完结
-
Sex differences in the Norwegian Tenecteplase Trial (NOR‐TEST)
6个月前
已关闭
-
Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial
6个月前
已完结
-
A guide to complement biology, pathology and therapeutic opportunity
7个月前
已完结